Belief BioMed Group, a Shanghai-based gene therapy specialist, has announced the first subject dosing in a regulatory clinical study for its in-house developed adeno-associated virus (AAV) gene therapy, BBM-H803, for the treatment of hemophilia A in China. This marks a significant step forward in addressing the unmet medical need for advanced treatments for hemophilia A patients in the country.
BBM-H803, which received orphan drug designation (ODD) status in the United States in December 2022, is the company’s second product to gain clinical trial approval in China. Notably, there is currently no AAV gene therapy available in China to treat hemophilia A, highlighting the potential impact of BBM-H803 on the treatment landscape for this condition.- Flcube.com
